Greenhalgh D G, Sprugel K H, Murray M J, Ross R
Department of Surgery, University of Washington, Seattle.
Am J Pathol. 1990 Jun;136(6):1235-46.
To examine the effects of recombinant growth factors in vivo, impaired wound healing was studied in genetically diabetic C57BL/KsJ-db/db mice. Large full-thickness skin wounds made on the backs of these mice exhibited significant delays in the entry of inflammatory cells into the wound, the formation of granulation tissue, and in wound closure when compared to their nondiabetic littermates. Recombinant human platelet-derived growth factor (rPDGF-BB, 1 or 10 micrograms), recombinant human basic fibroblast growth factor (rbFGF, 1 micrograms), or combinations of both were applied topically to the wounds for 5 to 14 days after wounding. Diabetic mouse wounds treated with rPDGF-BB or rbFGF had many more fibroblasts and capillaries in the wound bed at 10 and 21 days than did wounds treated with the vehicle alone. The animals treated with growth factors also had significantly greater wound closure at 21 days than those treated with the vehicle. Combinations of rPDGF-BB and rbFGF improved all parameters of healing but not to a greater extent than either growth factor alone. The effectiveness of rPDGF-BB and rbFGF suggest that recombinant growth factors may be useful in the treatment of patients with deficient wound repair.
为了研究重组生长因子在体内的作用，我们在遗传性糖尿病C57BL/KsJ-db/db小鼠中研究了受损的伤口愈合情况。与非糖尿病同窝小鼠相比，在这些小鼠背部制造的大面积全层皮肤伤口在炎症细胞进入伤口、肉芽组织形成以及伤口闭合方面均表现出显著延迟。在受伤后5至14天，将重组人血小板衍生生长因子（rPDGF-BB，1或10微克）、重组人碱性成纤维细胞生长因子（rbFGF，1微克）或两者的组合局部应用于伤口。在第10天和第21天，用rPDGF-BB或rbFGF治疗的糖尿病小鼠伤口床中的成纤维细胞和毛细血管比仅用赋形剂治疗的伤口多得多。用生长因子治疗的动物在第21天的伤口闭合也明显大于用赋形剂治疗的动物。rPDGF-BB和rbFGF的组合改善了所有愈合参数，但程度并不比单独使用任何一种生长因子更大。rPDGF-BB和rbFGF的有效性表明，重组生长因子可能对伤口修复不足的患者治疗有用。
